ESC 365 - What is the evidence and which aldosterone antagonist should a patient with HFmrEF receive?

HFA Premium Access

What is the evidence and which aldosterone antagonist should a patient with HFmrEF receive?

Session: Current pharmacological treatment of heart failure with mid-range ejection fraction

Topic: Chronic Heart Failure

Speaker: Professor F. Martinez (Cordoba, AR)

Event: Heart Failure 2021

Congress Presentation

Add to my library

About the speaker

Professor Felipe Martinez

DAMIC Medical Institute, Cordoba (Argentina)

4 presentations

0 follower

3 more presentations in this session

What is the evidence and which beta-blocker should a patient with HFmrEF receive?

Speaker: Professor A. Stewart Coats (Sydney, AU)

What other pharmacological treatments should a patient with HFmrEF receive?

Speaker: Professor L. Lund (Stockholm, SE)

Current pharmacological treatment of heart failure with mid-range ejection fraction - discussion.

Access the full session

Current pharmacological treatment of heart failure with mid-range ejection fraction

Speakers: Professor F. Martinez, Professor A. Stewart Coats, Professor L. Lund

About the event

Heart Failure 2021

29 June - 1 July 2021

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources